These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21585705)

  • 1. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
    Ahn MJ; Tsai CM; Hsia TC; Wright E; Chang JW; Kim HT; Kim JH; Kang JH; Kim SW; Bae EJ; Kang M; Lister J; Walzer S
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():22-33. PubMed ID: 21585705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
    Giuliani G; Grossi F; de Marinis F; Walzer S
    Lung Cancer; 2010 Aug; 69 Suppl 1():S11-7. PubMed ID: 20727457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
    Goulart B; Ramsey S
    Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.
    Chang JW; Thongprasert S; Wright E; Tsang K; Kim HT; Ahn MJ; Kim JH; Kang JH; Kim SW; Walzer S
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():13-21. PubMed ID: 21585704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
    Bischoff HG; Heigener DF; Walzer S; Nuijten M
    Lung Cancer; 2010 Aug; 69 Suppl 1():S18-23. PubMed ID: 20727458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
    J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
    Earle CC; Evans WK
    Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
    Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
    Hillner BE; Smith TJ
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
    Lee EK; Revil C; Ngoh CA; Lister J; Kwon JM; Park MH; Park SJ; Park YS; Shin SJ; Lee MA; Lee NS; Zang DY; Bae EJ; Kang MJ
    Clin Ther; 2012 Jun; 34(6):1408-19. PubMed ID: 22657254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
    Thongprasert S; Tinmanee S; Permsuwan U
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
    Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
    Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
    Ardizzoni A; Tiseo M; Boni L; Vincent AD; Passalacqua R; Buti S; Amoroso D; Camerini A; Labianca R; Genestreti G; Boni C; Ciuffreda L; Di Costanzo F; de Marinis F; Crinò L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Mattioli R; Cafferata MA; Camisa R; Smit EF
    J Clin Oncol; 2012 Dec; 30(36):4501-7. PubMed ID: 23109689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.